Townsquare Capital LLC Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Townsquare Capital LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,941 shares of the medical research company's stock after selling 2,273 shares during the period. Townsquare Capital LLC's holdings in IQVIA were worth $1,954,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Sanctuary Advisors LLC raised its stake in shares of IQVIA by 60.8% in the third quarter. Sanctuary Advisors LLC now owns 5,498 shares of the medical research company's stock worth $1,303,000 after purchasing an additional 2,079 shares during the last quarter. World Investment Advisors LLC purchased a new position in IQVIA during the 3rd quarter worth $14,633,000. Arvest Bank Trust Division bought a new position in shares of IQVIA during the third quarter valued at about $21,079,000. Wilmington Savings Fund Society FSB bought a new stake in IQVIA in the 3rd quarter worth about $2,310,000. Finally, Tidal Investments LLC boosted its stake in shares of IQVIA by 9.3% in the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after buying an additional 509 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $4.78 during midday trading on Friday, reaching $143.66. 3,302,597 shares of the company's stock traded hands, compared to its average volume of 1,408,683. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The stock has a 50 day moving average of $176.42 and a 200 day moving average of $196.62. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on IQV shares. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.